Medicure在2025年第三季度的收入上升至820万美元，但尽管主要药品销售增长，净亏损仍扩大至140万美元。 Medicure's revenue rose to $8.2M in Q3 2025, but net loss widened to $1.4M despite growth in key drug sales.

Medicure Inc. 报告称截至2025年9月30日的季度净收入为820万美元，较去年同期的520万美元有所增长，主要得益于新药房收购以及ZYPITAMAG®和BRENZAVVY®销售的增长。 Medicure Inc. reported $8.2 million in net revenue for the quarter ended September 30, 2025, up from $5.2 million in the same period last year, driven by new pharmacy acquisitions and increased sales of ZYPITAMAG® and BRENZAVVY®. 由于通用竞争,AGGRASTAT的收入从190万美元下降到100万美元。 Revenue from AGGRASTAT® fell to $1.0 million from $1.9 million due to generic competition. 该公司的净亏损为140万美元,即每股0.13美元,而一年前的利润为680 000美元,经调整的EBITDA则恶化为负597 000美元。 The company posted a net loss of $1.4 million, or $0.13 per share, compared to a $680,000 profit a year earlier, with adjusted EBITDA worsening to negative $597,000. 研发支出达到717 000美元,支持了第3阶段对MC-1的试验,以弥补PNPO短缺。 R&D spending reached $717,000, supporting a Phase 3 trial for MC-1 in PNPO deficiency.